Pharmaceutical News

RSS

Scientists to explore effectiveness of tadalafil drug to tackle vascular dementia

Scientists are to explore whether drugs usually used to treat erectile problems by expanding blood vessels could become the next major way to tackle the dementia epidemic.

11 Dec 2014

Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

The drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy.

11 Dec 2014

New study reveals how COX-2 inhibitors can increase risk of heart attack in arthritis patients

A class of drug for treating arthritis - all but shelved over fears about side effects - may be given a new lease of life, following the discovery of a possible way to identify which patients should avoid using it.

11 Dec 2014

Prolongz drug achieves No. 1 spot in the personal care category

Prolongz, the all-natural FDA registered over-the-counter homeopathic drug that helps in the prevention of premature ejaculation, has been ranked No. 1 in the personal care category for July, August and September of 2014 by the Jordan Whitney Greensheet.

10 Dec 2014

Mylan announces U.S. launch of Celecoxib Capsules

Mylan Inc. today announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.

10 Dec 2014

Targeted therapy with radiopharmaceuticals has great potential for cancer treatment

Cancer therapy can be much more effective using a new way to customize nuclear medicine treatment, researchers say in the December 2014 issue of The Journal of Nuclear Medicine. The process could also be useful for other diseases that could benefit from targeted radiation.

10 Dec 2014

Study: Simeprevir-based therapy proves effective in treating chronic HCV infection

Researchers at Penn Medicine, in collaboration with a multi-center international team, have shown that a protease inhibitor, simeprevir, a once a day pill, along with interferon and ribavirin has proven as effective in treating chronic Hepatitis C virus infection (HCV) as telaprevir with interferon and ribavirin, the standard of care in developing countries.

10 Dec 2014

Drug proves effective at inhibiting growth of drug-resistant bacteria

A treatment pioneered at the University of Pittsburgh Center for Vaccine Research is far more effective than traditional antibiotics at inhibiting the growth of drug-resistant bacteria, including so-called "superbugs" resistant to almost all existing antibiotics, which plague hospitals and nursing homes.

10 Dec 2014

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

Nektar Therapeutics reported partner AstraZeneca today announced that MOVENTIG (naloxegol) has been granted Marketing Authorisation by the European Commission for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).

9 Dec 2014

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

After more than a decade-long wait, the revolutionary therapy that provided a new lease of life to millions of patients suffering from rheumatoid arthritis and other auto immune disorders globally will now be accessible to patients in India. Zydus Cadila becomes the first company anywhere in the world to launch the biosimilar of Adalimumab - the world's largest selling therapy.

9 Dec 2014

Opioid tramadol can increase hospitalization risk for hypoglycemia

The opioid pain-reliever tramadol appears to be associated with an increased risk of hospitalization for hypoglycemia, a potentially fatal condition caused by low blood sugar, according to a report published online by JAMA Internal Medicine.

9 Dec 2014

Doctors prescribe fewer opioids for pain as prescription drug abuse rises

Nine in 10 primary care physicians say that prescription drug abuse is a moderate or big problem in their communities and nearly half say they are less likely to prescribe opioids to treat pain compared to a year ago, new Johns Hopkins Bloomberg School of Public Health research suggests.

9 Dec 2014

Study shows seasonal flu vaccines may protect individuals against many different viruses

Seasonal flu vaccines may protect individuals not only against the strains of flu they contain but also against many additional types, according to a study published this week in mBio, the online open-access journal of the American Society for Microbiology.

9 Dec 2014

Study: Injectable 3D vaccines could help prevent cancer, infectious disease

One of the reasons cancer is so deadly is that it can evade attack from the body's immune system, which allows tumors to flourish and spread. Scientists can try to induce the immune system, known as immunotherapy, to go into attack mode to fight cancer and to build long lasting immune resistance to cancer cells.

9 Dec 2014

Low doses of fluoxetine could hold key to preventing PMS symptoms

Low doses of fluoxetine - better known as the anti-depressant Prozac - could hold the key to preventing PMS symptoms, an international team of researchers has found.

8 Dec 2014

Spark Therapeutics, Pfizer partner to develop SPK-FIX for potential treatment of hemophilia B

Spark Therapeutics, a late-stage gene therapy company developing treatments for debilitating genetic diseases, announced today that it has entered into a global collaboration with Pfizer Inc. for the development and potential commercialization of SPK-FIX, a development program advancing proprietary, bio-engineered adeno-associated virus (AAV) vectors for the potential treatment of hemophilia B.

8 Dec 2014

Daiichi Sankyo releases new formulation of LIXIANA 60 mg Tablets

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new formulation of LIXIANA 60 mg Tablets (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban, approval to market: September 26, 2014; NHI drug price listing: November 25, 2014) in Japan for the recently approved indications: the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and the treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism (PE)].

8 Dec 2014

Vitamin C may reduce exercise-induced bronchoconstriction and respiratory symptoms

Physical activity increases oxidative stress, and therefore, as an antioxidant vitamin C might have particularly evident effects on people who are participating in vigorous exercise. In several studies, vitamin C administration attenuated the increases in oxidative stress markers caused by exercise. Furthermore, vitamin C is involved in the metabolism of histamine, prostaglandins, and cysteinyl leukotrienes, all of which appear to be mediators in the pathogenesis of exercise-induced bronchoconstriction.

8 Dec 2014

iTeos Therapeutics, Pfizer form strategic collaboration for cancer immunotherapeutics

iTeos Therapeutics SA announced today a strategic collaboration with Pfizer Inc. pursuant to which iTeos will license to Pfizer rights to iTeos' pre-clinical compounds targeting Indoleamine 2,3-dioxygenase (IDO1) and Tryptophan 2,3-dioxygenase (TDO2). Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates.

8 Dec 2014

Researchers gain new insights into potential treatment for Alzheimer's disease

It is estimated that about 35 million people worldwide currently suffer from dementia and it is expected that the number will increase to 135 million by the year 2050. The disease is already one of the most common health problems in the elderly, which is why experts predict that the numbers of people affected will increase over time.

8 Dec 2014

Pharmaceutical News

Scientists to explore effectiveness of tadalafil drug to tackle vascular dementia

Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

New study reveals how COX-2 inhibitors can increase risk of heart attack in arthritis patients

Prolongz drug achieves No. 1 spot in the personal care category

Mylan announces U.S. launch of Celecoxib Capsules

Targeted therapy with radiopharmaceuticals has great potential for cancer treatment

Study: Simeprevir-based therapy proves effective in treating chronic HCV infection

Drug proves effective at inhibiting growth of drug-resistant bacteria

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

Zydus Cadila becomes world's first company to launch biosimilar of Adalimumab

Opioid tramadol can increase hospitalization risk for hypoglycemia

Doctors prescribe fewer opioids for pain as prescription drug abuse rises

Study shows seasonal flu vaccines may protect individuals against many different viruses

Study: Injectable 3D vaccines could help prevent cancer, infectious disease

Low doses of fluoxetine could hold key to preventing PMS symptoms

Spark Therapeutics, Pfizer partner to develop SPK-FIX for potential treatment of hemophilia B

Daiichi Sankyo releases new formulation of LIXIANA 60 mg Tablets

Vitamin C may reduce exercise-induced bronchoconstriction and respiratory symptoms

iTeos Therapeutics, Pfizer form strategic collaboration for cancer immunotherapeutics

Researchers gain new insights into potential treatment for Alzheimer's disease

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News